Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong

Dova Pharmaceuticals (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through its wholly owned subsidiary, AkaRx, granting Shanghai Fosun Pharmaceutical Industrial Development a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (SHA:600196) (HKG:02196), the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.

As quoted in the press release:

“Fosun Pharma is a highly qualified partner, and we are excited to work with them as we look to expand avatrombopag internationally,” said Alex Sapir, President and Chief Executive Officer of Dova. “Fosun Pharma is a strong pharmaceutical company in China and a growing international player. They have the resources and experience to assist us with the marketing authorization process in order to maximize the distribution of avatrombopag in mainland China and Hong Kong.”

Click here to read the full press release.